MX2023005039A - Derivados de 2-hidroxicicloalcan-1-carbamoilo que inhiben la galectina-3. - Google Patents
Derivados de 2-hidroxicicloalcan-1-carbamoilo que inhiben la galectina-3.Info
- Publication number
- MX2023005039A MX2023005039A MX2023005039A MX2023005039A MX2023005039A MX 2023005039 A MX2023005039 A MX 2023005039A MX 2023005039 A MX2023005039 A MX 2023005039A MX 2023005039 A MX2023005039 A MX 2023005039A MX 2023005039 A MX2023005039 A MX 2023005039A
- Authority
- MX
- Mexico
- Prior art keywords
- galectin
- hydroxycycloalkane
- inhibiting
- carbamoyl derivatives
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/12—Triazine radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2020080681 | 2020-11-02 | ||
| EP2021053133 | 2021-02-10 | ||
| PCT/EP2021/080276 WO2022090544A1 (en) | 2020-11-02 | 2021-11-01 | Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005039A true MX2023005039A (es) | 2023-05-16 |
Family
ID=78414042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005039A MX2023005039A (es) | 2020-11-02 | 2021-11-01 | Derivados de 2-hidroxicicloalcan-1-carbamoilo que inhiben la galectina-3. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12291520B2 (enExample) |
| EP (1) | EP4237419A1 (enExample) |
| JP (1) | JP7834746B2 (enExample) |
| KR (1) | KR20230104190A (enExample) |
| AU (1) | AU2021370994A1 (enExample) |
| CA (1) | CA3197095A1 (enExample) |
| IL (1) | IL302421A (enExample) |
| MX (1) | MX2023005039A (enExample) |
| TW (1) | TWI910255B (enExample) |
| WO (1) | WO2022090544A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102863667B1 (ko) | 2019-08-09 | 2025-09-23 | 이도르시아 파마슈티컬스 리미티드 | (2-아세트아미딜)티오-베타-d-갈락토피라노시드 유도체 |
| US12404295B2 (en) | 2019-08-09 | 2025-09-02 | Idorsia Pharmaceuticals Ltd | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives |
| MA56883B1 (fr) | 2019-08-15 | 2025-04-30 | Idorsia Pharmaceuticals Ltd | Dérivés de 2-hydroxycycloalcane-1-carbamoyle |
| CN114585619B (zh) | 2019-08-29 | 2024-09-27 | 爱杜西亚药品有限公司 | α-D-吡喃半乳糖苷衍生物 |
| WO2022073969A1 (en) | 2020-10-06 | 2022-04-14 | Idorsia Pharmaceuticals Ltd | Spiro derivatives of alpha-d-galactopyranosides |
| JP7844491B2 (ja) | 2021-02-09 | 2026-04-13 | イドルシア・ファーマシューティカルズ・リミテッド | ヒドロキシヘテロシクロアルカン－カルバモイル誘導体 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100172D0 (sv) | 2001-01-22 | 2001-01-22 | Ulf Nilsson | New inhibitors against galectins |
| SE0401301D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| KR102231732B1 (ko) | 2012-10-10 | 2021-03-23 | 갈렉틴 테라퓨틱스, 인크. | 당뇨병성 신장병증 및 관련 질환의 치료를 위한 갈락토스 갈래의 탄수화물 화합물 |
| IN2015DN02573A (enExample) | 2012-10-31 | 2015-09-11 | Galecto Biotech Ab | |
| EP2919802A4 (en) | 2012-11-15 | 2016-09-14 | Univ Tufts | METHOD, COMPOSITIONS AND KITS FOR TREATING, MODULATING OR PREVENTING ANGIOGENESIS OR FIBROSIS IN A PATIENT USING A GALECTINE PROTEIN HEMMER |
| CA2970062C (en) | 2015-01-30 | 2023-02-28 | Galecto Biotech Ab | Alpha-d-galactoside inhibitors of galectins |
| ES2734713T3 (es) | 2015-07-06 | 2019-12-11 | Gilead Sciences Inc | Moduladores Cot y métodos de utilización de los mismos |
| CN109563119A (zh) | 2016-07-12 | 2019-04-02 | 格莱克特生物技术公司 | 半乳糖凝集素的α-D-半乳糖苷抑制剂 |
| KR102626669B1 (ko) | 2017-05-12 | 2024-01-17 | 갈랙틴 사이언시즈, 엘엘씨 | 질환의 예방 및 치료를 위한 화합물 및 이의 용도 |
| CA3062649A1 (en) | 2017-05-12 | 2018-11-15 | Galectin Sciences, Llc | Compounds for the treatment of systemic insulin resistance disorders and the use thereof |
| US11267811B2 (en) | 2017-09-27 | 2022-03-08 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| WO2019075045A1 (en) | 2017-10-11 | 2019-04-18 | Bristol-Myers Squibb Company | INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3 |
| JP2021501180A (ja) | 2017-10-31 | 2021-01-14 | ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＧａｌｅｃｔｉｎ Ｓｃｉｅｎｃｅｓ， ＬＬＣ | 全身インスリン抵抗性障害の治療のためのセレノガラクトシド化合物およびその使用 |
| CN113366007A (zh) | 2018-10-15 | 2021-09-07 | 格莱克特生物技术公司 | 半乳糖凝集素的半乳糖苷抑制剂 |
| CN113286632A (zh) | 2018-10-15 | 2021-08-20 | 格莱克特生物技术公司 | 半乳糖凝集素的半乳糖苷抑制剂前药 |
| US11447517B2 (en) | 2018-11-21 | 2022-09-20 | Galecto Biotech Ab | Galactoside inhibitor of galectins |
| JP7547345B2 (ja) * | 2018-12-27 | 2024-09-09 | グリコミメティクス， インコーポレイテッド | ガレクチン－３阻害性ｃ－グリコシド |
| EP3947407B1 (en) * | 2019-03-26 | 2024-06-12 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| US12269819B2 (en) | 2019-04-10 | 2025-04-08 | Bristol-Myers Squibb Company | Small molecule inhibitors of Galectin-3 |
| JP7674276B2 (ja) | 2019-07-03 | 2025-05-09 | ガレクト バイオテック エービー | ガレクチンの新規なガラクトシド阻害剤 |
| CA3143078A1 (en) | 2019-07-05 | 2021-01-14 | Galecto Biotech Ab | Novel galactoside inhibitor of galectins |
| US12404295B2 (en) | 2019-08-09 | 2025-09-02 | Idorsia Pharmaceuticals Ltd | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives |
| KR102863667B1 (ko) | 2019-08-09 | 2025-09-23 | 이도르시아 파마슈티컬스 리미티드 | (2-아세트아미딜)티오-베타-d-갈락토피라노시드 유도체 |
| MA56883B1 (fr) | 2019-08-15 | 2025-04-30 | Idorsia Pharmaceuticals Ltd | Dérivés de 2-hydroxycycloalcane-1-carbamoyle |
| CN114585619B (zh) | 2019-08-29 | 2024-09-27 | 爱杜西亚药品有限公司 | α-D-吡喃半乳糖苷衍生物 |
| WO2022073969A1 (en) | 2020-10-06 | 2022-04-14 | Idorsia Pharmaceuticals Ltd | Spiro derivatives of alpha-d-galactopyranosides |
| JP7844491B2 (ja) | 2021-02-09 | 2026-04-13 | イドルシア・ファーマシューティカルズ・リミテッド | ヒドロキシヘテロシクロアルカン－カルバモイル誘導体 |
| WO2022184755A1 (en) | 2021-03-03 | 2022-09-09 | Idorsia Pharmaceuticals Ltd | Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives |
-
2021
- 2021-11-01 US US18/251,273 patent/US12291520B2/en active Active
- 2021-11-01 TW TW110140598A patent/TWI910255B/zh active
- 2021-11-01 IL IL302421A patent/IL302421A/en unknown
- 2021-11-01 AU AU2021370994A patent/AU2021370994A1/en active Pending
- 2021-11-01 KR KR1020237017985A patent/KR20230104190A/ko active Pending
- 2021-11-01 JP JP2023526360A patent/JP7834746B2/ja active Active
- 2021-11-01 CA CA3197095A patent/CA3197095A1/en active Pending
- 2021-11-01 MX MX2023005039A patent/MX2023005039A/es unknown
- 2021-11-01 EP EP21799065.4A patent/EP4237419A1/en active Pending
- 2021-11-01 WO PCT/EP2021/080276 patent/WO2022090544A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA3197095A1 (en) | 2022-05-05 |
| TW202233609A (zh) | 2022-09-01 |
| JP2023547241A (ja) | 2023-11-09 |
| IL302421A (en) | 2023-06-01 |
| KR20230104190A (ko) | 2023-07-07 |
| AU2021370994A1 (en) | 2023-06-29 |
| TWI910255B (zh) | 2026-01-01 |
| US20230348442A1 (en) | 2023-11-02 |
| WO2022090544A1 (en) | 2022-05-05 |
| EP4237419A1 (en) | 2023-09-06 |
| US12291520B2 (en) | 2025-05-06 |
| JP7834746B2 (ja) | 2026-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022550338A1 (en) | 2-hydroxycycloalkane-1-carbamoyl derivatives | |
| SA522431777B1 (ar) | مشتقات ألفا -d- جالاكتو بيرانوسيد | |
| JOP20230113A1 (ar) | مشتقات ثلاثية الكربوكساميد كمثبطات prmt5 | |
| MX2021004000A (es) | Derivados de piperidina. | |
| JOP20230138A1 (ar) | مثبطات prmt5 | |
| MX2023004033A (es) | Espiro derivados de alfa-d-galactopiranosidos. | |
| MX2021005463A (es) | Derivados de espiro-sulfonamida como inhibidores de la proteina de leucemia de celula mieloide 1 (mcl-1). | |
| MX2024012980A (es) | Derivados heterociclicos triciclicos, composiciones y usos de los mismos | |
| MX2022013890A (es) | Sintesis y derivados de acido boronico, formas polimorficas y usos terapeuticos de los mismos. | |
| CL2023002322A1 (es) | Derivados de hidroxiheterocicloalquil-carbamoilo | |
| PH12021551873A1 (en) | Hydroxypyridoxazepines as nrf2 activators | |
| PH12019502562A1 (en) | N-substituted indole derivatives | |
| ZA202304541B (en) | Cdk inhibitors and their use as pharmaceuticals | |
| GEP20247670B (en) | 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents | |
| MX389786B (es) | Derivados de 4-metil 7-{[5-heterociclilpirazina-2-il]amino}1,2- dihidro-1,6-naftiridina-5-ona como compuestos inhibidores de cdk4/6 y el uso de los mismos para el tratamiento de cáncer. | |
| MX390747B (es) | Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico. | |
| MX2022016263A (es) | Derivados de ciclobutil-urea. | |
| PH12022552727A1 (en) | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2a AND THEIR METHODS OF USE | |
| MX2025012818A (es) | Derivados de heterociclicos triciclicos, composiciones y usos de estos | |
| MX2025014449A (es) | Derivados de heteroarilo como inhibidores de receptores de dominio de discoidina (ddr) | |
| MX2021015727A (es) | Derivados de piridin-3-ilo. | |
| MX2025006508A (es) | Inhibidores de kras g12d y usos de estos | |
| MX2023011057A (es) | Derivados de indolina como inhibidores de receptores de dominio de discoidina 1 (ddr1) y receptores de dominio de discoidina 2 (ddr2). | |
| MX2025000310A (es) | Nuevos derivados de espirociclohexano, composiciones farmaceuticas que los contienen y sus usos como inhibidores antiapoptoticos | |
| CL2023001138A1 (es) | Derivados de 2-hidroxicicloalcan-1-carbamoilo inhibidores de galectina-3 |